Ketamine for depression: all studies (page 20)

Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes.

Journal of Intensive Care Medicine April 16, 2026 Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi et al.

BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU...

DOI: 10.1177/08850666261438474 Full text Depression Ketamine Hemodynamic stability Intensive care unit

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Journal of Affective Disorders April 15, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al. 4 citations

Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...

DOI: 10.1016/j.jad.2025.121081 Full text Depressive disorder Ketamine Drug administration schedule Long-term potentiation +2

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Journal of Affective Disorders April 15, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.

Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...

DOI: 10.1016/j.jad.2025.121132 Full text Esketamine Treatment-resistant depression Target trial emulation

Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.

Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation

This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...

DOI: 10.1038/s41398-026-04032-3 Full text Ketamine Major depressive disorder Humans Antidepressive agents +5

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression.

Reviews on recent clinical trials April 7, 2026 Ritika Saun, Aakriti Garg, Mohd Ashif Khan

Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD. The search strategy adhered to PRISMA...

DOI: 10.2174/0115748871407261251215071206 Full text Mdd Esketamine Major depressive disorder Severe depression +2

Esketamine prevents postpartum depression after cesarean section: a Meta-analysis

Yixue xinzhi zazhi April 2, 2026 Yao Wenzhuang, Zhang Hanyun, Liu Suman et al.

Objective To systematically evaluate the efficacy and safety of Esketamine on postpartum depression (PPD) in cesarean section women.Methods Databases including PubMed, Embase, Web of Science, The Cochrane Library, CBM, CNKI, WanFang and VIP were searched from inception to March 2025 for RCTs investigating the impact of Esketamine on PPD in cesarean section parturients. RevMan 5.4 and Stata 18.0...

DOI: 10.12173/j.issn.1004-5511.202505094 Full text Esketamine Cesarean section Postpartum depression Patient-controlled intravenous analgesia +1

Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.

Focus (American Psychiatric Publishing) April 1, 2026 Rachel Fremont, Marcella Corwin, Greta Kandel et al.

Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...

DOI: 10.1176/appi.focus.20250046 Full text Depression Esketamine Academic psychiatry Antidepressants

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

Focus (American Psychiatric Publishing) April 1, 2026 Naim Zaki, Li Nancy Chen, Rosanne Lane et al.

Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3...

DOI: 10.1176/appi.focus.26024111 Full text

Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study.

PLoS Medicine April 1, 2026 Yifan Li, Vivien Kin Yi Chan, Mark Jit et al.

Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of...

DOI: 10.1371/journal.pmed.1005047 Full text

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

European Journal of Psychotraumatology April 1, 2026 Maud Rothärmel, Lila Mekaoui, François Kazour et al. 1 citation

Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for TRD, but its efficacy on comorbid TRD-PTSD remains...

DOI: 10.1080/20008066.2025.2609425 Full text Treatment-resistant depression Esketamine nasal spray Post-traumatic stress disorder Real-life data +2

Research